Spinal Muscular Atrophy: The Treatment Approved
暂无分享,去创建一个
Spinal muscular atrophy (SMA) is a rare genetic neuromuscular disorder resulting in progressive muscle weakness and atrophy. It is universally fatal, especially if the respiratory muscles are involved leading to repetitive aspiration and respiratory failure. Historically, the treatment for this disease was only supportive. Herein we describe an adult patient who presented with worsening weakness and fatigue and was subsequently diagnosed with spinal muscular atrophy. Increased awareness of this condition and a new treatment modality is required.
[1] R. Finkel,et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study , 2016, The Lancet.
[2] Jacqueline Montes,et al. Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy , 2016, Neurology.
[3] W. Arnold,et al. Spinal muscular atrophy: Diagnosis and management in a new therapeutic era , 2015, Muscle & nerve.
[4] J. Melki,et al. Spinal muscular atrophy. , 1997, Current opinion in neurology.